Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Gao, Jingchun ^a   Zhao, Yi ^a   Lv, Yunyi ^a   Chen, Yamin ^a   Wei, Bing ^a   Tian, Jianxin ^a   Yang, Zhihai ^a   Kong, Fandou ^a   Pang, Jian ^a   Liu, Jiwei ^a   Shi, Hong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer cells; Cell cycle; MAPK ERK; Mirk Dyrk1B; SiRNA

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MIRK PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPEPTIDE; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEOMICS; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING;

EID: 84872164775     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-2     Document Type: Article

References (21)

1. Friedman E. Mirk/Dyrk1B in cancer. J Cell Biochem 2007, 102:274-279. 10.1002/jcb.21451, 17583556.
2. Deng X, Ewton DZ, Pawlikowski B, Maimone M, Friedman E. Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation. J Biol Chem 2003, 278:41347-41354. 10.1074/jbc.M306780200, 12902328.
3. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J Biol Chem 2004, 279:22498-22504. 10.1074/jbc.M400479200, 15010468.
4. Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 2004, 279:27790-27798. 10.1074/jbc.M403042200, 15075324.
5. Hu J, Nakhla H, Friedman E. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2. Int J Cancer 2011, 129:307-318. 10.1002/ijc.25692, 20857490.
6. Jin K, Ewton DZ, Park S, Hu J, Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. J Biol Chem 2009, 284:22916-22925. 10.1074/jbc.M109.035519, 2755699, 19542220.
7. Deng X, Ewton DZ, Friedman E. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species. Cancer Res 2009, 69:3317-3324. 10.1158/0008-5472.CAN-08-2903, 2669831, 19351855.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
9. Gao J, Yang X, Yin P, Hu W, Liao H, Miao Z, Pan C, Li N. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer. Int J Oncol 2012, 40:1203-1209.
10. Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther 2009, 8:1671-1679. 10.4161/cbt.8.17.9322, 19633423.
11. Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. Cancer Res 2006, 66:4149-4158. 10.1158/0008-5472.CAN-05-3089, 16618736.
12. Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, Liu X, Mankin H, Duan Z. The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 2012, 31:552-558.
13. Hu J, Friedman E. Depleting mirk kinase increases cisplatin toxicity in ovarian cancer cells. Genes Cancer 2012, 1:803-811.
14. Gao J, Niwa K, Sun W, Takemura M, Lian Z, Onogi K, Seishima M, Mori H, Tamaya T. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 2004, 95:901-907. 10.1111/j.1349-7006.2004.tb02200.x, 15546508.
15. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003, 22:4150-4165. 10.1038/sj.onc.1206479, 12833138.
16. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203. 10.1016/j.cell.2007.11.025, 18083107.
17. Kim D, Won J, Shin DW, Kang J, Kim YJ, Choi SY, Hwang MK, Jeong BW, Kim GS, Joe CO, Chung SH, Song WJ. Regulation of Dyrk1A kinase activity by 14-3-3. Biochem Biophys Res Commun 2004, 323:499-504. 10.1016/j.bbrc.2004.08.102, 15369779.
18. Alvarez M, Altafaj X, Aranda S, de la Luna S. DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding. Mol Biol Cell 2007, 18:1167-1178. 10.1091/mbc.E06-08-0668, 1838983, 17229891.
19. Lochhead PA, Sibbet G, Morrice N, Cleghon V. Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell 2005, 121:925-936. 10.1016/j.cell.2005.03.034, 15960979.
20. Lee K, Deng X, Friedman E. Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res 2000, 60:3631-3637.
21. Lim S, Jin K, Friedman E. Mirk protein kinase is activated by MKK3 and functions as a transcriptional activator of HNF1alpha. J Biol Chem 2002, 277:25040-25046. 10.1074/jbc.M203257200, 11980910.